Lymphoma Clinical Trials

Showing 721-740 of 2,926 trials

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT03583424

This phase I/II trial studies the side effects and best dose of venetoclax when given together with carmustine, etoposide, cytarabine, and melphalan before stem cell transplant in treating participants with non-Hodgkin lymphoma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as venetoclax, carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow.

Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more

Ohio State University Comprehensive Cancer Center19 participantsStarted Sep 2018

Columbus, Ohio, United States

RECRUITINGPhase 1/2

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

NCT06594640

This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma

Diffuse Large B-cell Lymphoma

Institute of Hematology & Blood Diseases Hospital, China108 participantsStarted May 2024

Tianjin, Tianjin Municipality, China

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Related Searches

A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

Zanubrutinib Combined With G-CVP in Previously Untreated FL

Tempus Priority Study: A Pan-tumor Observational Study

Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma